Vivani Medical, Inc. filed a Form 8-K on November 12, 2026, reporting top-line results from its SLIM-1 Phase 1 clinical trial of NPM-139, a semaglutide implant, alongside its third quarter 2026 financial results.

Key Highlights

  • No treatment-related adverse events were reported in the NPM-139 group across the four-week SLIM-1 trial, according to the filing.
  • Five of ten Wegovy participants experienced treatment-related adverse events, all of which were gastrointestinal, the filing disclosed.
  • Maximum semaglutide levels following a single NPM-139 administration were measured at approximately 16 days, compared with approximately 2.4 days after the first weekly Wegovy injection.
  • Observed weight loss over four weeks was 0.79% in the NPM-139 group and 0.82% in the Wegovy group, per the filing.
  • Phase 2 dose-ranging trial is anticipated to begin in 2027, the company disclosed, subject to its cautionary forward-looking language.
  • SLIM-1 was an open-label, active-controlled trial conducted at a single study center in Australia with 20 total participants, 10 per group.

SLIM-1 Trial Results and NPM-139 Development Plans at Vivani Medical

According to the filing, SLIM-1 was a four-week, open-label, active-controlled Phase 1 clinical trial conducted at a single study center in Australia. The trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of low-dose NPM-139, Vivani Medical's investigational semaglutide implant, in otherwise healthy overweight or obese participants. Ten participants received NPM-139 and ten received the starting dose of Wegovy, described as 0.25 mg of semaglutide administered by weekly injection. Changes in body weight were also measured.

The filing reported that no adverse events were deemed treatment-related in the NPM-139 group. In the Wegovy group, five of ten participants experienced treatment-related adverse events, all gastrointestinal in nature. No serious adverse events were reported in either group. On pharmacokinetics, the filing stated that NPM-139 showed no rapid increases in drug exposure, with peak semaglutide levels occurring at approximately 16 days following a single administration, versus approximately 2.4 days following the first weekly Wegovy injection. Observed weight loss over the four-week period was 0.79% for NPM-139 participants and 0.82% for Wegovy participants.

The filing noted that NPM-139 is a subdermal implant utilizing the company's proprietary NanoPortal technology and "is being designed for once- or twice-yearly administration for chronic weight management." Based on these top-line results, the company disclosed plans to advance NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027, and to explore potential clinical development in GLP-1-naive patients. The filing identified NASDAQ:VANI as the trading symbol for Vivani Medical's common stock, par value $0.0001 per share, listed on the Nasdaq Capital Market. The filing also noted that Vivani Medical reported its third quarter 2026 financial results, with the press release attached as Exhibit 99.1. The filing contains forward-looking statements that are the company's own and subject to its stated cautionary language regarding risks and uncertainties.

What Was Disclosed

Vivani Medical filed an 8-K on November 12, 2026, disclosing positive top-line safety and pharmacokinetic results from its SLIM-1 Phase 1 trial of NPM-139, a semaglutide implant, and reporting third quarter 2026 financial results via attached press releases and a corporate slide presentation.